Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)

非酒精性脂肪性肝炎临床研究网络 (NASH CRN)

• 批准号: 10017185
• 负责人: ANNA MAE ELIZABETH DIEHL
• 金额: $ 36.01万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-05-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10017185
• 关键词: Address; Adult; Advanced Development; Affect; Antioxidants; Automobile Driving; Bile Acids; Biological; Biological Markers; Cardiovascular system; Cells; Child; Childhood; Cholesterol; Clinical; Clinical Management; Clinical Research; Clinical Sciences; Clinical Trials; Diagnosis; Diagnostic tests; Disease; Disease Progression; Dyslipidemias; Economic Burden; Ensure; Environmental Risk Factor; Epidemic; Erinaceidae; FDA approved; Fibrosis; Funding; Future; Hepatic Stellate Cell; Heritability; Human; Incidence; Institutional Review Boards; Intervention; Knowledge; Laboratory Study; Ligands; Lipids; Lipoproteins; Liver; Liver Fibrosis; Liver Regeneration; Malignant Neoplasms; Mission; Monitor; Multi-Institutional Clinical Trial; National Institute of Diabetes and Digestive and Kidney Diseases; Natural History; North America; Pathogenesis; Pathway interactions; Patients; Pediatric Hospitals; Pharmacotherapy; Phenotype; Population Study; Positioning Attribute; Prevention; Prospective Studies; Protocols documentation; Public Health; Recovery; Reporting; Research; Role; Scientist; Signal Pathway; Signal Transduction; Site; Testing; Translational Research; Work; adverse outcome; atorvastatin; burden of illness; chronic liver disease; clinical application; clinical research site; cohort; cost; cost effective; effective intervention; effective therapy; improved; innovation; insight; liver injury; liver repair; member; mortality; non-alcoholic fatty liver; non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; novel; novel marker; personalized medicine; prevent; prospective; randomized placebo controlled trial; smoothened signaling pathway; success

The epidemic of nonalcoholic steatohepatitis (NASH) will not be constrained without collaborative efforts to identify, prevent, and treat the factors that drive NASH pathogenesis and progression in humans. To address this challenge the NIDDK established the NASH Clinical Research Network (NASH CRN), a consortium devoted to advancing clinical and translational science pertinent to adult and pediatric NASH. The CRN is widely considered to be a leader in the NASH field because it has developed the world’s largest, best-characterized, and longest prospectively-followed cohort of adult and pediatric NASH patients and done several definitive prospective randomized placebo-controlled trials (RCTs) in NASH subjects. Moving forward, the CRN will leverage information generated by this work to advance development of diagnostic tests, biomarkers of disease progression, and safe, cost-effective treatments for NASH. This competitive renewal application from the Duke/Lurie Children’s Hospital site details our site’s plans for the work that we will accomplish during the next funding cycle as CRN members. In addition to our detailed approach to ensure success of all CRN activities (Aim 1), we further propose a new multi-center RCT evaluating atorvastatin as a generic “repurposed” drug for the treatment of NASH (Aim 2) and related translational science to provide mechanistic information about how statins impact NASH (Aim 3). The latter two projects are natural extensions of our earlier CRN studies which demonstrated the importance of Hedgehog, a lipid-regulated signaling pathway, in determining progression of NASH and NASH-related fibrosis. Accomplishment of these Aims will advance NASH CRN missions by further delineating NASH natural history and identifying novel interventions that safely and cost-effectively prevent and treat NASH.

非酒精性脂肪性肝炎（NASH）的流行将不会受到限制，如果没有合作的努力